Authors
Andrea Picchianti-Diamanti, Alessandra Rai, Stella Mrmić, Sofia Marotta, Eugenio Santacroce, Maurizio Alimandi, Pankaj Trivedi, Eleni Anastasiadou
Published in
Clinical and experimental immunology. Jul 13, 2026. Epub Jul 13, 2026.
Abstract
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease driven by immune dysregulation, chronic inflammation, and loss of immune tolerance. Increasing evidence suggests that non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, and circular RNAs, are involved in the fine regulation of immune responses, epigenetic changes, and cytokine signaling in SLE. Their altered expression has been associated with disease activity, specific clinical phenotypes, and treatment response, supporting their potential as biomarkers. Epstein-Barr virus (EBV), a long-suspected contributor to SLE, may further shape disease through persistent immune activation, molecular mimicry, and modulation of host ncRNA pathways. In this review, we examine how EBV and ncRNA dysregulation may converge in autoreactive B cells and other immune compartments to promote the loss of tolerance and the development of clinically distinct forms of SLE. We also discuss the implications of this axis for biomarker development and emerging therapeutic strategies, including personalized immune-targeted approaches.
PMID:
42439858
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0